Analysts expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to announce earnings per share of ($0.24) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.28). Dicerna Pharmaceuticals posted earnings of ($0.92) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 73.9%. The company is expected to issue its next quarterly earnings results on Thursday, November 1st.

Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.79 million.

DRNA has been the topic of a number of research reports. BidaskClub downgraded Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. HC Wainwright upgraded Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Wednesday, August 15th. Chardan Capital restated a “hold” rating and set a $14.50 price target on shares of Dicerna Pharmaceuticals in a research report on Monday, August 13th. ValuEngine downgraded Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 2nd. Finally, Stifel Nicolaus raised their price target on Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $17.41.

NASDAQ DRNA traded down $0.81 during trading hours on Tuesday, reaching $15.99. 1,378,292 shares of the stock traded hands, compared to its average volume of 830,546. Dicerna Pharmaceuticals has a 1 year low of $4.19 and a 1 year high of $17.98. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.40 and a current ratio of 5.40.

In other news, insider James B. Weissman sold 2,301 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $17.50, for a total value of $40,267.50. Following the transaction, the insider now owns 26,781 shares in the company, valued at $468,667.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Dennis Langer sold 14,531 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $16.00, for a total value of $232,496.00. Following the completion of the transaction, the director now owns 29,064 shares in the company, valued at approximately $465,024. The disclosure for this sale can be found here. Company insiders own 19.85% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DRNA. Cubist Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $102,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $113,000. Caxton Corp purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $125,000. Jane Street Group LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $136,000. Finally, Verition Fund Management LLC purchased a new position in shares of Dicerna Pharmaceuticals in the first quarter worth about $141,000. Hedge funds and other institutional investors own 87.02% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Featured Article: Penny Stocks, Risk and Reward Factors

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.